However, long-term experience with other ERT approaches, such as PSMA- and SSTR-directed ERT, suggests that these therapies rarely can lead to hematological toxicities, including myelodysplastic syndromes, or organ dysfunctions such as renal insufficiency 46, 47. This evidence concerns the gene FOLH1 and myelodysplastic syndrome.